Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Hang Quach(The University of Melbourne), H. Miles Prince(Peter MacCallum Cancer Centre), Mark J. Smyth(Peter MacCallum Cancer Centre), Simon J. Harrison(Peter MacCallum Cancer Centre), A. Keith Stewart(The University of Texas MD Anderson Cancer Center), David Ritchie(Peter MacCallum Cancer Centre), Paul J. Neeson(The University of Melbourne)
Cited by 586
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Immune surveillance of tumors
|Journal of Clinical Investigation|2007|1.4k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
|Annals of Oncology|2014|1.3k
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719